Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction

A technology for stable angina pectoris and acute myocardial infarction, applied in the field of biochemistry, to achieve the effect of improving the convenience of diagnosis, accurate and reliable results, and high sensitivity

Active Publication Date: 2016-06-08
齐炼文
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] No one has used plasma metabolite

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction
  • Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction
  • Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Screening Characterization of Differential Metabolites in Plasma Between Patients with Unstable Angina and Acute Myocardial Infarction

[0029] 1. Objects and methods

[0030] 1. The source of the specimen

[0031] After obtaining the consent of the patients, the peripheral venous blood plasma of 260 patients with unstable angina pectoris, 295 patients with acute myocardial infarction and 350 healthy people in Jiangsu Provincial People's Hospital from September 2010 to June 2015 were collected. Confirmed by coronary angiography. The age and gender of healthy people were matched with patients with unstable angina and patients with acute myocardial infarction. All patients with unstable angina, patients with acute myocardial infarction and healthy people had normal heart, lung, liver, kidney and hematopoietic functions.

[0032] The time of blood collection was in the morning on an empty stomach.

[0033] 2. Main reagents

[0034] Acetonitrile and formic a...

Embodiment 2

[0055] Example 2: Construction of ROC curve to verify the ability of 9 differential metabolites to diagnose and distinguish between unstable angina and acute myocardial infarction

[0056] Receiver operating curve (ROC) method was used for verification, and the ability to diagnose and distinguish patients with acute myocardial infarction and unstable angina was judged by the expression levels of differential metabolites in the plasma of patients with acute myocardial infarction and patients with unstable angina pectoris . The results showed that N-phenylpropionyl-L-glutamine, dihydrosphingosine, arachidonic acid, arachidonic acid, glycocholic acid, lysophosphatidylcholine (14:0), tryptophan Nine differential metabolites of arginine-leucine tripeptide, lysophosphatidylcholine (18:2) and lysophosphatidylcholine (20:3) are individually used in the diagnosis of patients with acute myocardial infarction and unstable The ability of patients with angina pectoris is strong, and the a...

Embodiment 3

[0067] Embodiment 3: the preparation of detection kit

[0068] A detection kit has been prepared based on the metabolic markers provided by the present invention, and the kit includes the following components:

[0069] Standards of metabolic markers: including N-phenylpropionyl-L-glutamine, dihydrosphingosine, arachidonic acid, arachidonic acid, glycocholic acid, lysophosphatidylcholine (14: 0), tryptophan arginine leucine tripeptide, lysophosphatidylcholine (18:2) and lysophosphatidylcholine (20:3), each standard product is packaged separately;

[0070] Plasma metabolite extraction solvent: 100% acetonitrile and 20% acetonitrile aqueous solution (for UPLC-Q / TOF-MS sample preparation); a mixed solution of methanol, chloroform and water in a ratio of 2.5:1:1, methoxyaminopyridine and N-Methyl-N-trimethylsilyl trifluoroacetamide (for GC-Q / MS sample preparation); 20% acetonitrile aqueous solution can be used as dissolved standard in UPLC-Q / TOF-MS screening and characterization ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction, comprising one or more of N-phenylalanyl-L-glutamine, sphinganine, arachidonic acid, eicosatrienoic acid, glycocholic acid, lysophosphatidylcholine (14:0), tryptophan-arginine-leucine tripeptide, lysophosphatidylcholine (18:2), and lysophosphatidylcholine (20:3). In the single use of diagnosing and distinguishing patients with acute myocardial infarction and patients with unstable angina pectoris, each ROC (receiver operating characteristic) AUC (area under the curve) is greater than 0.7, and clinical diagnostic significance is provided; in the joint use for diagnosis, AUC further increases as a joint quantity increases, a highest AUC up to 0.991 is obtained in a case of nine members jointed, and sensitivity and specificity are respectively 99.2% and 98.9% under an optimal cutoff value. The metabolic marker can accurately diagnose and distinguish unstable angina pectoris and acute myocardial infarction, with high accuracy and high sensitivity and specificity.

Description

technical field [0001] The invention belongs to the field of biochemistry and relates to metabolic markers for diagnosis and classification of coronary heart disease, in particular to a group of metabolic markers for diagnosing and distinguishing between unstable angina pectoris and acute myocardial infarction. Background technique [0002] Coronary heart disease, also known as ischemic heart disease, involves atherosclerosis in the arteries supplying myocardial blood, that is, coronary atherosclerotic lesions cause vascular lumen narrowing or plaque formation or even rupture and complete blockage, resulting in myocardial ischemia and hypoxia. Or necrosis leads to cardiac ischemic disease, which leads to a series of serious cardiovascular events such as clinical angina pectoris and myocardial infarction. Coronary heart disease is the main killer of human health. It has the characteristics of high incidence rate, high disability rate, high recurrence rate, high mortality rate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/88G01N30/06G01N30/02
CPCG01N30/02G01N30/06G01N30/88G01N2030/025G01N2030/027G01N2030/8822
Inventor 齐炼文朱伟秦勇陈彦
Owner 齐炼文
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products